Literature DB >> 22014981

Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.

Jennifer Nam Choi1.   

Abstract

Chemotherapy and its cutaneous side effects are an increasingly common source of iatrogenic injury to the skin, hair, and nails. Cutaneous changes are among the most common side effects from treatment with particular targeted chemotherapeutic agents, especially those that target the epidermal growth factor receptor and small molecule multikinase inhibitors. Less common, but growing in recognition, are the development of secondary cutaneous neoplasms and subacute cutaneous lupus erythematosus as a result of chemotherapy. There is considerable overlap of the multiple entities described as a side effect from conventional chemotherapeutic agents; therefore, the term "toxic erythema of chemotherapy" can be used as an easily understood name.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014981     DOI: 10.1016/j.clindermatol.2011.08.032

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  5 in total

Review 1.  Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Authors:  Devron R Shah; Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

2.  Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition.

Authors:  Sabrina M Smith; Philip B Milam; Stephanie K Fabbro; Alejandro A Gru; Benjamin H Kaffenberger
Journal:  JAAD Case Rep       Date:  2016-12-07

3.  Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.

Authors:  William Queiroz Guimarães Wiegandt Ceglio; Marina Mattos Rebeis; Marcela Ferreira Santana; Denis Miyashiro; Jade Cury-Martins; José Antônio Sanches
Journal:  An Bras Dermatol       Date:  2021-11-26       Impact factor: 1.896

4.  Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients.

Authors:  Zeynep Utlu; Handan Bilen
Journal:  Postepy Dermatol Alergol       Date:  2021-10-22       Impact factor: 1.837

5.  Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.

Authors:  Alessandra Ferro; Angela Filoni; Alberto Pavan; Giulia Pasello; Valentina Guarneri; PierFranco Conte; Mauro Alaibac; Laura Bonanno
Journal:  Front Med (Lausanne)       Date:  2021-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.